US FDA emphasized in a recent warning to consumers that the number of adverse event reports on women with breast-implanted associated anaplastic large cell lymphoma (BIA-ALCL) worldwide has increased by about 246 reports, since last year.
FDA’s Device Center division of general surgery director Binita Ashar stated in the advisory that, as of September 2018, FDA received 660 total medical device reports on BIA-ALCL cases...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?